Detailed In-situ Investigation of the Electrochemical Processes in $Li_2FeTiO_4$ Chatodes
| Autor: | Kuezma, M., Dominko, R., Hanzel, D., Kodre, A., Arcon, I., Meden, A., Gaberscek, M. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Adolescent rufinamide therapeutic use [Triazoles] drug therapy [Epilepsy] Triazoles therapeutic use [Anticonvulsants] methods [Drug Therapy Combination] Young Adult Treatment Outcome Double-Blind Method Child Preschool ddc:540 Drug Evaluation Humans Female Anticonvulsants Longitudinal Studies Child |
| Zdroj: | Journal of the Electrochemical Society 156, A809-A816 (2009). doi:10.1149/1.3205458 |
| DOI: | 10.1149/1.3205458 |
| Popis: | This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests.Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had > or = 50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%).In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|